The table above summarizes the beneficial effects of SGLT2 inhibitors administration in patients with heart failure, with various grades of ejection fraction or CKD obtained in large clinical trials demonstrating that the hemodynamic effects discussed above reflect an improved clinical outcome for the patient. This evidence concerns the gene SLC5A2 and chronic kidney disease.